MTSR_OUT_1 [2025-04-29 10:29:57 -0400] 3902 Bytes | 982 tokens | Cum: 982 tkns (12.28% of 8k)
==========================================================================

Booyah, my friends! It's already 10:29 AM on Tue Apr 29, 2025, and I've got my eyes locked on Metsera (MTSR), pushing up to $22.25 from $19.81. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: Metsera (MTSR)
IPO: 2025-01-31 (2 Months Ago)
Market Cap: $1,530,581,691
Shares Outstanding: 105,050,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.

Here’s a list of headlines for Metsera:

Apr-26-25 08:50AM - Novo Nordisk: Examining Tariff And Pricing Risks
Mar-26-25 07:00AM - Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
Mar-15-25 04:42PM - Metsera, Inc. (MTSR): Among Top Insider Purchases Last Month
Mar-06-25 10:13AM - Is Metsera, Inc. (MTSR) Among Stocks With At Least $20 Million In Insider Spending Recently?
Mar-03-25 02:50PM - Metsera, Inc. (MTSR): Among Stocks With At Least $10 Million In Insider Spending Recently
Mar-01-25 05:02AM - Q4 2024 Amneal Pharmaceuticals Inc Earnings Call
Feb-26-25 07:00AM - Metsera to Present at TD Cowen's 45th Annual Health Care Conference
Feb-25-25 02:04PM - Wall Street bullish on Metsera following January IPO on obesity drug pipeline
Feb-19-25 02:50PM - Metsera (MTSR): Among Stocks Insiders Spent The Most Money On Recently
Feb-05-25 04:01PM - Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares
Jan-30-25 08:13PM - Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs
Jan-30-25 08:13PM 06:53PM - Metsera Announces Pricing of Initial Public Offering
Jan-30-25 08:13PM 02:57PM - Metsera, Maze secure combined $415 million in IPOs

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Metsera (MTSR).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

MTSR_OUT_3 [2025-04-29 10:29:58 -0400] 909 Bytes | 301 tokens | Cum: 1285 tkns (16.06% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-24T17:05:54Z - 12 Health Care Stocks Moving In Thursday's Intraday Session - CERo Therapeutics Hldgs (NASDAQ:CERO),...
A2 - 2025-04-23T16:58:48Z - Metsera (NASDAQ:MTSR) Trading Up 4.7% - Still a Buy?...
A3 - 2025-04-20T16:28:35Z - Hertz Global And Webull Stocks Are Among Top Mid-Cap Gainers Last Week (Apr 14-Apr 18): Are The Othe...
A4 - 2025-04-17T17:46:42Z - Metsera (NASDAQ:MTSR) Stock Price Up 7.4% - Time to Buy?...
A5 - 2025-04-16T14:46:28Z - Metsera (NASDAQ:MTSR) Shares Gap Up - Here's What Happened...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

MTSR_OUT_5 [2025-04-29 10:29:59 -0400] 1181 Bytes | 348 tokens | Cum: 1635 tkns (20.44% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Thursday's Intraday Session - CERo Therapeutics Hldgs (NASDAQ:CERO), BioSig Technologies (NASDAQ:BSGM)**Date: 2025-04-24Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44989024/12-health-care-stocks-moving-in-thursdays-intraday-sessionGainers CERo Therapeutics Hldgs CERO stock moved upwards by 37.6% to $1.1 during Thursday's regular session. The company's market cap stands at $5.9 million. TransCode Therapeutics RNAZ shares increased by 26.43% to $0.4. The market value of their outstanding shares is at $9.2 million. Zhengye Biotechnology ZYBT shares increased by 24.8% to $9.76. The market value of their outstanding shares is at $462.5 million. Community Health Sys CYH shares increased by 24.69% to $3.03. The market value of their outstanding shares is at $420.9 million. As pe

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MTSR_OUT_7 [2025-04-29 10:29:59 -0400] 1181 Bytes | 344 tokens | Cum: 1981 tkns (24.76% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): r the press release, Q1 earnings came out yesterday. BioSig Technologies BSGM shares increased by 23.43% to $0.79. The market value of their outstanding shares is at $19.1 million. Jaguar Health JAGX shares moved upwards by 19.94% to $8.0. The market value of their outstanding shares is at $5.3 million. Losers NuCana NCNA shares decreased by 26.3% to $0.66 during Thursday's regular session. The company's market cap stands at $3.9 million. Intensity Therapeutics INTS shares decreased by 23.85% to $0.99. The company's market cap stands at $15.0 million. Ensysce Biosciences ENSC shares declined by 16.08% to $3.08. The company's market cap stands at $5.0 million. Metsera MTSR stock fell 15.17% to $20.0. The company's market cap stands at $2.1 billion. Catheter Precision VTAK stock declined by 12.5% to $0.28. The market value of their outstanding shares is at $2.2 million. Plus Therapeutics P

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MTSR_OUT_9 [2025-04-29 10:30:00 -0400] 1181 Bytes | 386 tokens | Cum: 2369 tkns (29.61% of 8k)
==========================================================================

Showing A1 (chunk 3 of 4): STV shares decreased by 11.41% to $0.87. The market value of their outstanding shares is at $5.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGMBioSig Technologies Inc$0.780021.9%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum15.59Growth84.23Quality-Value2.67Price TrendShortMediumLongOverviewCEROCERo Therapeutics Holdings Inc$1.1240.1%CYHCommunity Health Systems Inc$3.0224.2%ENSCEnsysce Biosciences Inc$3.08-16.2%INTSIntensity Therapeutics Inc$0.9900-23.9%JAGXJaguar Health Inc$8.1021.4%MTSRMetsera Inc$20.02-15.1%NCNANuCana PLC$0.6587-26.0%PSTVPlus Therapeutics Inc$0.8828-10.2%RNAZTransCode Therapeutics Inc$0.380321.1%VTAKCatheter Precision Inc$0.3038-5.06%ZYBTZhengye Biotechnology

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MTSR_OUT_11 [2025-04-29 10:30:01 -0400] 357 Bytes | 107 tokens | Cum: 2478 tkns (30.98% of 8k)
==========================================================================

Showing A1 (chunk 4 of 4): Holding Ltd$9.8425.8%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MTSR_OUT_13 [2025-04-29 10:30:02 -0400] 1084 Bytes | 272 tokens | Cum: 2752 tkns (34.40% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-28 8-K Item7.01 Regulation FD Disclosure.

In addition, on April 28, 2025, the Company announced that Matthew Lang has been appointed as the Companys Chf Legal Off and Secretary. Mr. Lang previously served as the Chf Business Off and Chf Legal Off and Corporate Secret...

S2 - 2025-03-26 10-K It em 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following managements discussion and analysis of financial condition and results of operations together with our CONS financial statements and the related...

S3 - 2025-03-26 8-K Item2.02. Results of Oper and Fin Cond.

On March 26, 2025, Metsera, Inc. announced financial results for the three and twelve months ended December 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 9...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

MTSR_OUT_15 [2025-04-29 10:30:02 -0400] 1181 Bytes | 291 tokens | Cum: 3045 tkns (38.06% of 8k)
==========================================================================

Showing S1 (chunk 1 of 2): S1:
Item7.01 Regulation FD Disclosure.

In addition, on April 28, 2025, the Company announced that Matthew Lang has been appointed as the Companys Chief Legal Officer and Secretary. Mr. Lang previously served as the Chief Business Officer and Chief Legal Officer and Corporate Secretary of Lyell Immunopharma, Inc. (Lyell), a biotechnology company, from July 2023 to April 2025. Before joining Lyell, Mr. Lang held several executive officer positions at Myovant Sciences, Inc. (Myovant), a biotechnology company, between 2017 and 2023, most recently as Chief Administrative and Legal Officer. Mr. Lang also served as Managing Director and General Manager of Myovant Sciences GmbH in Basel, Switzerland. Mr. Lang was previously Vice President, Head of Global Litigation, Investigations, Employment Law and Information Governance at Gilead Sciences, Inc. (Gilead), from November 2009 to July 2017. Pri

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MTSR_OUT_17 [2025-04-29 10:30:03 -0400] 934 Bytes | 232 tokens | Cum: 3279 tkns (40.99% of 8k)
==========================================================================

Showing S1 (chunk 2 of 2): or to Gilead, from 2003 to 2009, Mr. Lang was an attorney at Dechert LLP. Mr. Lang received his B.A. in Classical Studies from Queens University at Kingston, Canada and his J.D. from the University of Pennsylvania Law School.

The information in this Item 7.01 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MTSR_OUT_19 [2025-04-29 10:30:10 -0400] 6963 Bytes | 1839 tokens | Cum: 5120 tkns (64.00% of 8k)
==========================================================================

This is our set of metrics for Metsera.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+------------------------+
| Volume: 112,993 | Perf Month: -23.11% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 936.35K | Perf Quarter: - | Short Float: 12.50% | ROE: - |
+---------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 0.77 | Index: RUT | Short Ratio: 8.02 | ROI: - |
+---------------------+-----------------------+------------------------+------------------------+
| RSI (14): 50.97 | Market Cap: 2.26B | Short Interest: 7.51M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+------------------------+
| ATR (14): 2.85 | Shs Outstand: 105.05M | Beta: - | EPS Surprise: -477.05% |
+---------------------+-----------------------+------------------------+------------------------+
| SMA20: 14.40% | Shs Float: 60.07M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+------------------------+
| SMA50: -11.39% | Inst Own: 1.87% | Sales past 5Y: 0.00% | Earnings: Mar 26 BMO |
+---------------------+-----------------------+------------------------+------------------------+
| SMA200: -14.64% | Insider Own: 42.81% | Employees: 81 | |
+---------------------+-----------------------+------------------------+------------------------+
| Perf Week: -0.69% | Insider Trans: 13.17% | Debt/Eq: 0.04 | |
+---------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading by Metsera officers or majority shareholders (if available).

Inside Trans: Metsera, Inc. (MTSR) by FMR LLC (Unknown Title) on 2025-02-03
- Common Stock: 1418606 shares at $N/A (I)
- Common Stock: 3120934 shares at $N/A (I)
- Series Seed Preferred Stock: 1418606 shares at $N/A (I)
- Series A Preferred Stock: 3120934 shares at $N/A (I)

Inside Trans: Metsera, Inc. (MTSR) by Wellington Biomedical Innovation Master Investors (Cayman) II L.P. (Unknown Title) on 2025-01-30
- Common Stock: 1857699 shares at $N/A (D)
- Series B Preferred Stock: 4365079 shares at $0 (D)

Inside Trans: Metsera, Inc. (MTSR) by ARCH Venture Partners XII, LLC (Unknown Title) on 2025-02-03
- Common Stock: 16006949 shares at $N/A (I)
- Common Stock: 7523682 shares at $N/A (I)
- Common Stock: 1432224 shares at $18 (I)
- Common Stock: 789998 shares at $18 (I)
- Series Seed Preferred Stock: 19933333 shares at $N/A (I)
- Series A Convertible Preferred Stock: 15000000 shares at $N/A (I)
- Series B Convertible Preferred Stock: 2678571 shares at $N/A (I)
- Series A Convertible Preferred Stock: 15000000 shares at $N/A (I)
- Series B Convertible Preferred Stock: 2678571 shares at $N/A (I)

Inside Trans: Metsera, Inc. (MTSR) by BERNS PAUL L (Unknown Title) on 2025-02-03
- Common Stock: 7523682 shares at $N/A (I)
- Common Stock: 789998 shares at $18 (I)
- Series A Convertible Preferred Stock: 15000000 shares at $N/A (I)
- Series B Convertible Preferred Stock: 2678571 shares at $N/A (I)

Inside Trans: Metsera, Inc. (MTSR) by Burow Kristina (Unknown Title) on 2025-02-03
- Common Stock: 16006949 shares at $N/A (I)
- Common Stock: 1432224 shares at $18 (I)
- Common Stock: 7523682 shares at $N/A (I)
- Common Stock: 789998 shares at $18 (I)
- Series Seed Preferred Stock: 19933333 shares at $N/A (I)
- Series A Convertible Preferred Stock: 15000000 shares at $N/A (I)
- Series B Convertible Preferred Stock: 2678571 shares at $N/A (I)
- Series A Convertible Preferred Stock: 15000000 shares at $N/A (I)
- Series B Convertible Preferred Stock: 2678571 shares at $N/A (I)

No transactions recorded.

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 22.275
Average Volume: 1230226.86
30-Day High: 27.22
30-Day Low: 13.08
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Metsera (MTSR).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Metsera.

2) MARKET_SCORE[]
This conversation was initiated because MTSR is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for MTSR.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, MTSR could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect MTSR to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Metsera.

11) ETHICAL_RATING[]
Rate Metsera’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Metsera.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

MTSR_IN_21 [2025-04-29 10:30:10 -0400] 126 Bytes | 29 tokens | Cum: 5351 tkns (66.89% of 8k)
==========================================================================

====================================
[2025-04-29 10:30:10] # Analysis Completed
Elapsed Time: 14.02 seconds